Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Webinar: Testing and Targeting Tumours with RET Alterations

ESMO-Webinar-Series-1000x250

ESMO Webinar: Testing and Targeting Tumours with RET Alterations

Chair: Fabrice Barlesi
Speakers: Frédérique Penault-Llorca, Carmen Belli, Alexander Drilon

Learning objectives

  • To provide an overview of validated methods for the detection of RET gene rearrangements and how to apply them rationally in the clinical practice  
  • To provide an update on clinical development of RET inhibitors (both unspecified, ie vandetanib, cabozantinib, etc, and specified) across broad range of tumours
  • To elaborate how to understand, assess and overcome the mechanisms of resistance to RET inhibitors

The programme is designed to offer an overview of research activities in this area and review the current status and future prospect of testing and targeting various tumours with RET alterations.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.